Elpiscience Biopharmaceuticals is focused on developing innovative cancer immunotherapies, leveraging advanced technologies to enhance the immune system's ability to combat tumors. Their proprietary platforms include the Bispecific Macrophage Engager (BiME®), which targets macrophages and tumor cells simultaneously to promote phagocytosis and direct tumor cell destruction. Additionally, Elpiscience employs the Acebody™ platform, which utilizes interchain disulfide bond engineering to improve the stability and pairing of bispecific antibodies, ensuring effective therapeutic properties. Their ElpiSource™ human antibody Fab library further accelerates the discovery process by providing a diverse range of antibody sequences without the need for animal immunization, thus streamlining the development timeline.

The company emphasizes a comprehensive approach to research and development, integrating translational medicine and advanced bioinformatics to optimize clinical outcomes. By utilizing cutting-edge techniques such as gene editing, single-cell sequencing, and a collection of tumor organoid models, Elpiscience aims to identify effective biomarkers and tailor patient selection for clinical studies. Their commitment to innovation is supported by a global clinical team experienced in executing large-scale trials, ensuring that their therapies can progress efficiently from discovery to clinical application.

China

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Elpiscience Biopharmaceuticals

Company Details